{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:06:16Z","timestamp":1780059976589,"version":"3.54.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014812","name":"Nordic Group BV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejca.2026.116588","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T08:06:20Z","timestamp":1771315580000},"page":"116588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Safety and feasibility of S-1 after capecitabine-induced toxicity in the adjuvant treatment of colon cancer patients: A population-based real-world study"],"prefix":"10.1016","volume":"237","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2323-7186","authenticated-orcid":false,"given":"Avin","family":"Ghedri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederieke H.","family":"van der Baan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0491-8623","authenticated-orcid":false,"given":"Johannes M.M.B.","family":"Otten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3986-4776","authenticated-orcid":false,"given":"Marloes A.G.","family":"Elferink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederiek","family":"Terheggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6687-5393","authenticated-orcid":false,"given":"Mathijs P.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0643-3790","authenticated-orcid":false,"given":"Anne M.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Koopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J.A.","family":"Punt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8187-7124","authenticated-orcid":false,"given":"Johannes J.M.","family":"Kwakman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116588_bib1","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/14656566.2016.1186649","article-title":"Oral drugs in the treatment of metastatic colorectal cancer","volume":"17","author":"Kwakman","year":"2016","journal-title":"Expert Opin Pharm"},{"key":"10.1016\/j.ejca.2026.116588_bib2","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Argil\u00e9s","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116588_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejca.2022.02.004","article-title":"Systematic review and non-inferiority meta-analysis of randomised phase II\/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer","volume":"166","author":"Derksen","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116588_bib4","first-page":"e229","article-title":"Updated survival analysis of the randomized phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group","volume":"18","author":"Kwakman","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ejca.2026.116588_bib5","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/annonc\/mdx122","article-title":"Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group","volume":"28","author":"Kwakman","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116588_bib6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2340\/1651-226X.2024.24023","article-title":"Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study)","volume":"63","author":"Kinos","year":"2024","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2026.116588_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100427","article-title":"Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study","volume":"7","author":"Osterlund","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.116588_bib8","first-page":"229","article-title":"Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer","volume":"21","author":"Punt","year":"2022","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ejca.2026.116588_bib9","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/0284186X.2016.1278459","article-title":"Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients","volume":"56","author":"Kwakman","year":"2017","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.ejca.2026.116588_bib10","unstructured":"European Medicines Agency. Teysuno. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/teysuno. 2022."},{"key":"10.1016\/j.ejca.2026.116588_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up \u2730","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116588_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101199","article-title":"Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer","volume":"8","author":"Punt","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.116588_bib13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1080\/0284186X.2016.1189094","article-title":"Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research","volume":"55","author":"Burbach","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2026.116588_bib14","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO Guidance for Reporting Oncology real-World evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116588_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2017.02.009","article-title":"Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group","volume":"76","author":"Kwakman","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116588_bib16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116588_bib17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/annonc\/mdf089","article-title":"First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil\/leucovorin","volume":"13","author":"Cassidy","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116588_bib18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-005-0178-1","article-title":"Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine","volume":"58","author":"Jensen","year":"2006","journal-title":"Cancer Chemother Pharm"},{"key":"10.1016\/j.ejca.2026.116588_bib19","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jaccao.2020.06.012","article-title":"How to diagnose and manage patients with fluoropyrimidine-induced chest pain: a single center approach","volume":"2","author":"Padegimas","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.ejca.2026.116588_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265767","article-title":"The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm","volume":"17","author":"Zafar","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2026.116588_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2468-1253(17)30297-2","article-title":"Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial","volume":"3","author":"Hamaguchi","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926003680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926003680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:33:28Z","timestamp":1777599208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926003680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":21,"alternative-id":["S0959804926003680"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116588","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and feasibility of S-1 after capecitabine-induced toxicity in the adjuvant treatment of colon cancer patients: A population-based real-world study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116588"}}